GlaxoSmithKline announced that its supplemental new drug application (sNDA) for Requip (ropinirole HCl) for the treatment of Restless Legs Syndrome (RLS) has been filed by the U.S. Food and Drug ...

Research Triangle Park, NC (December 15, 2004) – Study results published today in the journal Movement Disorders show that Requipâ(ropinirole HCl) Tablets effectively treats the symptoms of primary ...

Requip (ropinirole HCl) significantly improves symptoms of Restless Legs Syndrome (RLS), and is generally well tolerated, according to the results of a study presented at the 17th Associated ...

A new clinical practice guideline developed by the American Academy of Sleep Medicine provides updated recommendations for the treatment of restless legs syndrome. The guideline reflects the latest ...

Restless legs syndrome: a new practice guideline Evidence shows strong support for prescribing pramipexole, rotigotine, cabergoline, or gabapentin enacarbil to treat adults with restless legs syndrome ...

April 30, 2007 — Health Canada has approved an expanded indication for atorvastatin calcium tablets, allowing their use to reduce the risk for myocardial infarction in adult patients without ...

Patients who were prescribed drugs for restless legs syndrome (RLS) have said doctors did not warn them about significant side effects of the medication – including risky sexual behaviours and ...